Paradigm patent rejection, page-60

Thanks Dugiven. Understand now. Allows for instance J&J to refer to the confidential Bene processes for Elmiron (oral PPS) with the FDA under the DMF for their IND without Bene having to give this highly confidential information directly to J&J

We have one patent granted for the time being. Could be worse. All this prior patent art could be showing that PPS is not effective in OA!

But would like some more patents to come out of 008 study where there is less prior art on DMOAD for PPS. As others have clearly stated, pharma do like and understand patent IP protection even if we have strong commercial protection with exclusive supply/DMF.

Another person said big pharma would want to renegotiate the supply agreement with Bene. I find this unlikely as is the same deal structure that J&J have with Bene for Elmiron. Be hard for Bene to change a tried and used deal structure that has survived of 20 years.